Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population

Therapeutic Drug Monitoring

Volumn 20, Issue 3, 1998, Pages 243-247

  Kimura, Miyuki ^a,b   Ieiri, Ichiro ^a   Mamiya, Kohsuke ^a   Urae, Akinori ^b   Higuchi, Shun ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Kyushu Clinical Pharmacology Research Clinic   (Japan)

Author keywords

CYP2C19; CYP2C9; Cytochrome P450; Genetic polymorphism; Japanese

Indexed keywords

CYTOCHROME P2C19; CYTOCHROME P2C9; CYTOCHROME P450; DIAZEPAM; MEPHENYTOIN; OMEPRAZOLE; PHENYTOIN; TOLBUTAMIDE; UNCLASSIFIED DRUG; WARFARIN;

AMINO ACID SUBSTITUTION; ARTICLE; DRUG METABOLISM; ENZYME ANALYSIS; ENZYME METABOLISM; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; JAPAN; MAJOR CLINICAL STUDY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL;

ADULT; ALLELES; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PREVALENCE; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0031840217     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199806000-00001     Document Type: Article

References (28)

1. Kupfer A, Desmond P, Schenker S, Branch RA. Family study of a genetically determined deficiency of mephenytoin hydroxylation in man. Pharmacologist 1979;21:173.
2. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T. Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin, but not debrisoquine, hydroxylation phenotype. Clin Pharmacol Ther 1989;45:348-55.
3. Andersson T, Regardh CG, Dahl-Puustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990;12:415-6.
4. Scott J, Poffenbarger PL. Pharmacogenetics of tolbutamide metabolism in human. Diabetes 1979;28:41-51.
5. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 1991;175:1112-8.
6. Kaminsky LS, de Morais SMF, Faletto MB, Dunbar DA, Goldstein JA. Correlation of human cytochrome P4502C substrate specificities with primary structure: Warfarin as a probe. Mol Pharmacol 1993;43:234-9.
7. Alván G, Bechtel P, Iselius K, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39:533-7.
8. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38:402-8.
9. Horai Y, Nakano M, Ishizaki T, et al. Metoprolol and mephenytoin polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989;46:198-207.
10. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
11. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8.
12. Veronese ME, Doecke CJ, Mackenzie PI, et al. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J 1993;289:533-8.
13. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994;4:39-42.
14. Brockmoller J, Rost KL, Gross D, Schenkel A, Roots I. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon 5 G → A-splice site mutation. Pharmacogenetics 1995;5:80-8.
15. Wang S-L, Huang J-D, Lai M-D, Tsai J-J. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995;5:37-42.
16. Takakubo F, Kuwano A, Kondo I. Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese. Pharmacogenetics 1996;6:265-7.
17. Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995:5:358-63.
18. de Morais SMF, Goldstein JA, Xie H-G, et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995;58:404-11.
19. Masimirembwa C, Bertilsson L, Johansson I, Hasler JA, Ingelman-Sundberg M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995;57:656-61.
20. Furuya H, Fernandez-Salguero P, Gregory W, et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995;5:389-92.
21. Marinac JS, Balian JD, Foxworth JW, et al. Determination of CYP2C19 phenotype in black Americans with omeprazole: Correlation with genotype. Clin Pharmacol Ther 1996;60:138-44.
22. Bertilsson L, Kalow W. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations, but not in Chinese populations? Clin Pharmacol Ther 1993;53:608-10.
23. Ishizaki T, Sohn DR, Kobayashi K, et al. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 1994;16:214-5.
24. Ieiri I, Kubota T, Urae A, et al. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19ml in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 1996;59:647-53.
25. Kumana CR, Lauder IJ, Chan M, Ko W, Lin HJ. Differences in diazepam pharmacokinetics in Chinese and white Caucasians -relation to body lipid stores. Eur J Clin Pharmacol 1987;32:211-5.
26. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996;6:429-39.
27. Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN, Bertilsson L. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 1996;6:547-51.
28. Persson I, Aklillu E, Rodrigues F, Bertilsson L, Ingelman-Sundberg M. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 1996;6:521-6.